GSK receives FDA approval for Promacta

Dr Paolo Paoletti, president, Oncology, GSK

GlaxoSmithKline (GSK) announced that the USFDA has approved a supplemental New Drug Application (sNDA) for the once-daily use of Promacta (eltrombopag) in patients with severe aplastic anaemia (SAA), who have had an insufficient response to immunosuppressive - 

See more at: http://www.biospectrumindia.com/biospecindia/news/218690/gsk-receives-fda-approval-promacta